vatalanib

Phase 3Small molecule

Novartis

vatalanib is one of 289 small molecule programs targeting Cutaneous Melanoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

288

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cutaneous MelanomaActive, not recruiting

Malignant GliomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

MeningiomaActive, not recruiting

Pancreatic CancerActive, not recruiting

Prostate CancerActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Glioblastoma MultiformeActive, not recruiting

Cutaneous MelanomaPhase 2

Active, not recruiting

Malignant GliomaPhase 1

Active, not recruiting

Metastatic Colorectal CancerPhase 3

Active, not recruiting

MeningiomaPhase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Prostate CancerPhase 1/Phase 2

Active, not recruiting

Myelodysplastic SyndromesPhase 2

Active, not recruiting

Glioblastoma MultiformePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

vatalanib

Novartis

Phase 3

1 2

Novantrone

Pfizer

Preclinical

5 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Viagra

VViatris Specialty LLC

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer2 trials

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

Completed· Novartis logo

Novartis·Phase 3·NCT00056459·1,168 enrolled

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT00056446·855 enrolled

Patients With Advanced Solid Tumors2 trials

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Completed·MMayo Clinic·Phase 1·NCT00655655·96 enrolled

Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors

Completed·MMayo Clinic·Phase 1·NCT00390000·29 enrolled

Pancreatic Cancer1 trial

Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer

Completed·GGeorge Albert Fisher·Phase 1/2·NCT00185588·33 enrolled

Glioblastoma Multiforme1 trial

Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1/2·NCT00128700·20 enrolled

Cutaneous Melanoma1 trial

Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery

Completed·—·Phase 2·NCT00563823·34 enrolled

6 more indications

Malignant Glioma1 trial

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Completed·—·Phase 1·NCT00387933·37 enrolled

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00072475·155 enrolled

Meningioma1 trial

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Completed·NNorthwestern University·Phase 2·NCT00348790·25 enrolled

Prostate Cancer1 trial

Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

Terminated·UUniversity of California, San Francisco·Phase 1/2·NCT00293371·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for vatalanib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — vatalanib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for vatalanib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

vatalanib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic Colorectal Cancer2 trials

Patients With Advanced Solid Tumors2 trials

Pancreatic Cancer1 trial

Glioblastoma Multiforme1 trial

Cutaneous Melanoma1 trial

Malignant Glioma1 trial

Neuroendocrine Tumors1 trial

Metastatic Neuroendocrine Tumor1 trial

Myelodysplastic Syndromes1 trial

Meningioma1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News